Daily biotech intelligence: FDA actions, drug recalls, and recent research.
LENALIDOMIDE — Approved Sponsor: CIPLA · Application type: ORIG · Date: 20220906 · Priority: STANDARD
REVLIMID (LENALIDOMIDE) — Approved Sponsor: BRISTOL MYERS SQUIBB · Application type: SUPPL · Date: 20120312 · Priority: STANDARD
Unknown — Approved Sponsor: LUPIN · Application type: ORIG · Date: 20250916 · Priority: STANDARD
POMALYST (POMALIDOMIDE) — Approved Sponsor: BRISTOL · Application type: SUPPL · Date: 20160630 · Priority: STANDARD
Unknown — Approved Sponsor: ASTRAZENECA AB · Application type: SUPPL · Date: 20260427 · Priority: STANDARD
EPYSQLI (ECULIZUMAB-AAGH) — Approved Sponsor: SAMSUNG BIOEPIS CO LTD · Application type: SUPPL · Date: 20250902 · Priority: N/A
Unknown — Approved Sponsor: ACCORD HLTHCARE · Application type: SUPPL · Date: 20260427
POMALIDOMIDE — Approved Sponsor: BRECKENRIDGE · Application type: ORIG · Date: 20201030 · Priority: STANDARD
NUPLAZID (PIMAVANSERIN TARTRATE) — Approved Sponsor: ACADIA PHARMS INC · Application type: SUPPL · Date: 20230915 · Priority: STANDARD
LENALIDOMIDE — Approved Sponsor: BIOCON PHARMA · Application type: ORIG · Date: 20250303 · Priority: STANDARD
SUN PHARMACEUTICAL INDUSTRIES INC [Class II] — 20260422 Product: Fluocinonide, USP, 0.05% Cream, 30g tube, Rx only, Mfd by: Taro Pharmaceuticals Inc., Brampton, Onta Reason: Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. [Class II] — 20260422 Product: MGC Health, Menthol- Cough Suppressant, Oral Anesthetic, Cough Drops, Honey Lemon, 30-count bag, Dis Reason: This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufac
Owen Biosciences Inc. [Class II] — 20260422 Product: FHF Farmhouse Fresh, Midnight Clearing, NIGHT LOTION, 2.5% BENZOYL PEROXIDE ACNE TREATMENT, OTC a) 0 Reason: Chemical contamination: Presence of benzene
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. [Class II] — 20260422 Product: MGC Health, Menthol- Cough Suppressant, Oral Anesthetic, Cough Drops, Sugar Free, Honey Lemon, 25-co Reason: This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufac
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. [Class II] — 20260422 Product: Discount Drug Mart Food Market, Cough Drops, Menthol -Cough Suppressant Anesthetic, 30-count bag, Di Reason: This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufac
Mingyang Liu, Gabriele Farina, Asuman Ozdaglar · 2026-04-30 · cs.GT · cs.AI
Most familiar equilibrium concepts, such as Nash and correlated equilibrium, guarantee only that no single player can improve their utility by deviating unilaterally. They offer no guarantees against profitable coordinated deviations by coalitions. Although the literature proposes solution concepts that provide stability against multilateral deviat
Eyon Jang, Damon Falck, Joschka Braun · 2026-04-30 · cs.LG · cs.CL
Reinforcement learning (RL) has become essential to the post-training of large language models (LLMs) for reasoning, agentic capabilities and alignment. Successful RL relies on sufficient exploration of diverse actions by the model during training, which creates a potential failure mode: a model could strategically alter its exploration during trai
Tao Ge, Baolin Peng, Hao Cheng · 2026-04-30 · cs.AI · cs.CL
Realistic long-horizon productivity work is strongly conditioned on user-specific computer environments, where much of the work context is stored and organized through directory structures and content-rich artifacts. To scale synthetic data creation for such productivity scenarios, we introduce Synthetic Computers at Scale, a scalable methodology f
Himanshu Pandey, Ratikanta Behera · 2026-04-30 · cs.LG
In recent years, physics-informed neural networks (PINNs) have gained significant attention for solving differential equations, although they suffer from two fundamental limitations, namely, spectral bias inherent in neural networks and loss imbalance arising from multiscale phenomena. This paper proposes an adaptive wavelet-based PINN (AW-PINN) to
Emma Andrews, Sahan Sanjaya, Prabhat Mishra · 2026-04-30 · quant-ph · cs.LG
Machine learning models can learn from data samples to carry out various tasks efficiently. When data samples are adversarially manipulated, such as by insertion of carefully crafted noise, it can cause the model to make mistakes. Quantum machine learning models are also vulnerable to such adversarial attacks, especially in image classification usi
Haidong Zhao, Nikolaos Georgantas · 2026-04-30 · cs.LG
Machine learning (ML) inference serving systems host deep neural network (DNN) models and schedule incoming inference requests across deployed GPUs. However, limited support for task prioritization and insufficient latency estimation under concurrent execution may restrict their applicability in on-premises scenarios. We present \emph{Strait}, a se
Sriram Narayanan, Ziyu Jiang, Srinivasa Narasimhan · 2026-04-30 · cs.CV · cs.AI
Modern video diffusion models excel at appearance synthesis but still struggle with physical consistency: objects drift, collisions lack realistic rebound, and material responses seldom match their underlying properties. We present PhyCo, a framework that introduces continuous, interpretable, and physically grounded control into video generation. O
Grace T. Bai, Brandon B. Le · 2026-04-30 · cond-mat.soft · cs.LG
In this study, we use machine learning to classify and interpolate the phase structure of the Vicsek flocking model across the three-dimensional parameter space $(η,ρ,v_0)$. We construct a dataset of simulated parameter points and characterize each point using long-time dynamical observables. These observables are then used as inputs to a K-Means c
Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical school (STAT News) “Unfortunately, the resources don't exist to take every flat-earther to the International Space Station to change their mind,” a STAT reader writes.
Opinion: What do medical students think about their education? (STAT News) “No one's pulling the pieces together”: a conversation with medical students about preventive care education.
STAT+: Up and down the ladder: The latest comings and goings (STAT News) Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and…
STAT+: Axsome wins FDA nod for Alzheimer’s agitation (STAT News) Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more (STAT News) The FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versions
PFAS is still in some infant formula (STAT News) Casey Means out as surgeon general nominee, America's renewed fertility anxiety, and more health news
Opinion: The psychedelic revolution is leaving behind people of color (STAT News) Psychedelics’ potential as a form of treatment is virtually unmatched. But their promise faces both scientific uncertainty and thorny political questions.
‘Forever chemicals’ in baby formula? Scientists unpack FDA results (STAT News) FDA review confirmed overall safety of 16 brands of baby formula. In a STAT Q&A, experts unpack what low-level PFAS findings mean to worried moms.
STAT+: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more (STAT News) Efforts to make customized medicines at scale have hit commercial and regulatory roadblocks. Julia Vintarello is trying again.
Opinion: America is worrying about fertility again. But it’s not really about families (STAT News) Where the state once worried about too many births, it now worries about too few.
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA (BioPharma Dive) Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal (BioPharma Dive) Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.
This briefing is compiled automatically from FDA public APIs (openFDA), arXiv, and industry RSS feeds (STAT News, Fierce Biotech, BioPharma Dive, Nature, Science News). Not investment advice. Verify all data before making any decisions.